Valeant CEO not asked to appear before Senate hearing, company says; Philidor cuts 262 jobs;

@FiercePharma: #ICYMI yesterday: $TEVA to divest $1B in assets to clear antitrust hurdles to Allergan deal: Reuters. Story | Follow @FiercePharma

@CarlyHFierce: Lyxumia's CV results may help Sanofi's case for approval, but they won't score it points against SGLT2s. Story | Follow @CarlyHFierce

> Valeant Pharmaceuticals ($VRX) says that while it has been asked for info on drug pricing for a Senate hearing next week, its CEO J. Michael Pearson was not asked to appear and will not be testifying there. Story

> A Pennsylvania WARN notice indicates that 262 employees lost their jobs when specialty pharmacy Philidor Rx had to close after accusations that employees faked some prescriptions to push drugs for Valeant Pharmaceuticals, causing it to lose business. Story

> Amgen ($AMGN) has submitted its application to the EMA for its biosimilar of Humira. Release

> Samsung Bioepis, which is working on biosimilars with Biogen ($BIIB) and Merck ($MRK), has received approval in South Korea for its biosimilar of Johnson & Johnson's ($JNJ) autoimmune disease drug Remicade after receiving approval there for a biosimilar of Amgen's Enbrel. Release

Medical Device News

@FierceMedDev: Dx Digest: Report | Follow @FierceMedDev

@VarunSaxena2: I've never seen a team invent so many ways to lose as the Detroit Lions! I knew it was coming! Unsure of call but it's the Lions after all. | Follow @VarunSaxena2

@EmilyWFierce: Google Life Sciences CMO opens up about research plans. Story | Follow @EmilyWFierce

> NIH funds a trio of robots to improve health, life quality for the disabled. Report

> Troubled Insulet recalling additional 18 lots of wearable insulin pump due to needle failure. More

Biotech News

@FierceBiotech: Pfizer is shuttering another U.K. R&D outpost, ditching 120 jobs. Article | Follow @FierceBiotech

@JohnCFierce: Lilly pulls the plug on a massive insulin project in a blow to its diabetes pipeline. Story | Follow @JohnCFierce

@DamianFierce: this is good SEO. Link | Follow @DamianFierce

> Merck and Amgen team up in immuno-oncology with a pair of combo trials. News

> Shkreli's KaloBios buys an old drug with eyes on a lucrative FDA voucher. Article

> Startup raises $15M to turn an old diabetes drug into a potent cancer killer. Report

Suggested Articles

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.